Redx Pharma is a drug discovery and development company focused on creating new drugs for areas of unmet medical need such as cancer and immunology. As their portfolio rapidly matured, Redx recognised a need for expert safety input as well as ion channel screening data, to develop high quality clinical candidates.
ApconiX was engaged by Redx in 2016 as a strategic partner to provide nonclinical safety support to the portfolio. In this role, we provided ion channel screening services and project toxicology expertise to the Redx oncology, infection and inflammation business units.
Through this relationship, Redx had flexible access to the entire team of nonclinical safety experts, without needing to build this capability internally. Our experts worked closely with Redx scientists, to provide guidance on nonclinical safety and DMPK strategy, as well as gap analysis, data interpretation and advice on next steps. For the lead programs entering GLP toxicity studies, we worked with Redx to influence study design and decision-making, as well as data interpretation. We co-authored the submission documents and participated in regulatory agency interactions.
In this extremely successful partnership, we have developed a model relationship with Redx Pharma. For the two most advanced projects, one was successfully divested to a US biotech, and the other achieved a successful CTA, with the first cancer patients dosed in February 2018 (https://goo.gl/kfMv9p).
We continue to work closely with Redx to deliver the next wave of novel medicines to patients.